Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer.

Nature 2012 Jun;486(7404):532-6

Laboratory of Molecular Genetics, Institute for Cancer Research and Treatment, 10060 Candiolo (Torino), Italy.

A main limitation of therapies that selectively target kinase signalling pathways is the emergence of secondary drug resistance. Cetuximab, a monoclonal antibody that binds the extracellular domain of epidermal growth factor receptor (EGFR), is effective in a subset of KRAS wild-type metastatic colorectal cancers. After an initial response, secondary resistance invariably ensues, thereby limiting the clinical benefit of this drug. The molecular bases of secondary resistance to cetuximab in colorectal cancer are poorly understood. Here we show that molecular alterations (in most instances point mutations) of KRAS are causally associated with the onset of acquired resistance to anti-EGFR treatment in colorectal cancers. Expression of mutant KRAS under the control of its endogenous gene promoter was sufficient to confer cetuximab resistance, but resistant cells remained sensitive to combinatorial inhibition of EGFR and mitogen-activated protein-kinase kinase (MEK). Analysis of metastases from patients who developed resistance to cetuximab or panitumumab showed the emergence of KRAS amplification in one sample and acquisition of secondary KRAS mutations in 60% (6 out of 10) of the cases. KRAS mutant alleles were detectable in the blood of cetuximab-treated patients as early as 10 months before radiographic documentation of disease progression. In summary, the results identify KRAS mutations as frequent drivers of acquired resistance to cetuximab in colorectal cancers, indicate that the emergence of KRAS mutant clones can be detected non-invasively months before radiographic progression and suggest early initiation of a MEK inhibitor as a rational strategy for delaying or reversing drug resistance.

Download full-text PDF

Source
http://dx.doi.org/10.1038/nature11156DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3927413PMC
June 2012
86 Reads
427 Citations
42.351 Impact Factor

Publication Analysis

Top Keywords

resistance cetuximab
16
kras mutations
12
colorectal cancers
12
emergence kras
12
acquired resistance
12
resistance
9
kras mutant
8
secondary resistance
8
drug resistance
8
cetuximab colorectal
8
resistance anti-egfr
8
months radiographic
8
kras
8
colorectal cancer
8
cetuximab
5
colorectal
5
secondary kras
4
cancer understood
4
inhibition egfr
4
bases secondary
4

References

(Supplied by CrossRef)

F Ciardiello et al.
N. Engl. J. Med. 2008

CS Karapetis et al.
N. Engl. J. Med. 2008

DL Wheeler et al.
Oncogene 2008

S Benavente et al.
Clin. Cancer Res. 2009

C Li et al.
Oncogene 2009

H Hatakeyama et al.
PLoS ONE 2010

K Yonesaka et al.
Sci. Transl. Med. 2011

C Montagut et al.
Nature Med. 2012

M Moroni et al.
Lancet Oncol. 2005

W De Roock et al.
Lancet Oncol. 2010

F Diehl et al.
Nature Med. 2008

Similar Publications